

Thursday 23 June 2022

09.30 - 10.15 **Registration and welcome with coffee/tea**

10.15 - 10.25 **Opening by the chair of the NVED**

10.25 - 11.25 **Session I: Epidermal structure and function**

Session chair: Peter van den Akker (*UMCG*), Hanna Niehues (*Radboudumc*)

1. Marike van Gisbergen *MaastrichtUMC* Novel FAM83G mutations display deficient CK1a-binding in palmoplantar keratoderma.
2. Jos Smits *Radboudumc* Regulation of keratinocyte differentiation through aryl hydrocarbon receptor signaling involves the transient activation of TFAP2A.
3. Auke Otten *AmsterdamUMC* A genome-wide long noncoding RNA CRISPRi screen identifies PRANCR as a novel regulator of epidermal homeostasis.
4. Jos Smits *Radboudumc* CRISPR-Cas9 editing of human keratinocytes to resolve or confirm gene function: A showcase study for filaggrin null phenotype.

11.25 - 12.10: **Marcel Jonkman lecture** by dr. Joost Meijer, *UMCG*

12.10 - 13:15 **Lunch**

13.15 - 14.15 **Session II: Multi-omic approaches for investigative dermatology**

Session chair: Remco van Doorn (*LUMC*) + Klara Mosterd (*MUMC*)

5. Safa Najidh *LUMC* Improved Sézary cell detection and novel insights into immunophenotypic and molecular heterogeneity in Sézary syndrome.
6. Elisabetta Michielon *AmsterdamUMC* Cellular cross-talk-induced secretion of interleukin-10 (IL-10) in an organotypic human melanoma-in-skin model skews monocyte differentiation towards an M2-like phenotype.
7. Inger Kreuger *LUMC* Multi-omics analysis of mutant NRAS-induced senescence in human melanocytes.
8. Wouter Ouwerkerk *AmsterdamUMC* Genetic association between vitiligo genetic susceptibility and response to immune checkpoint inhibitor therapy in advanced melanoma patients: early results of the IO-GEM consortium.

14.15 - 14.30 Break (stretch your legs)

14.30 - 15.30 **Session III: Diagnostics in dermatology**

Session chair: Marcel Bekkenk (*AmsterdamUMC*) + Eموke Racz (*UMCG*)

9. Tobias Sangers *ErasmusMC* Limited impact of diagnostic delay due to COVID-19 on melanoma and squamous cell carcinoma tumor characteristics in the Netherlands: A nationwide pathology registry analysis.
10. Fieke Adan *MaastrichtUMC* Optical coherence tomography versus punch biopsy for diagnosis of basal cell carcinoma: a randomized diagnostic trial.

11. Anna Smak Gregoor *ErasmusMC* The impact of an artificial intelligence (AI) based mobile health application on dermatological care consumption in the Netherlands: a retrospective cohort study.
12. Bertine Huisman *CHDR* Integrin $\alpha v \beta 6$ as a target for tumor-specific imaging of vulvar squamous cell carcinoma and adjacent premalignant lesions.

15.30 - 16.45 Poster presentations and networking session I (with coffee and tea)
(selection for poster walks by jury)

- P1. Mehran Aghdam (*UMCU*) Recombinant human C1 esterase inhibitor as prophylactic treatment of idiopathic non-histaminergic angioedema: A phase 1 trial and follow-up.
- P2. Joline Bogaard (*AmsterdamUMC*) Saliva as potential treatment for burns: Assessing antimicrobial properties of saliva and donor variation of burn patients.
- P3. Sven van Egmond (*ErasmusMC*) Telehealth for older adults with skin disease: A qualitative exploration of Dermatologists' experiences & recommendations for improving care.
- P4. Andrew Morrison (*AmsterdamUMC*) A 3D organotypic model to study human lymph node FRC-DC interactions.
- P5. Noa van den Brink (*Radboudumc*) Local dermatitis upon tapestripping and vaseline treatment of healthy human skin is attenuated by coal tar: Insights into AHR-targeting therapies for inflammatory skin diseases.
- P6. Lin Shang (*AmsterdamUMC*) Dynamic host-microbiome interactions in reconstructed human oral mucosa with representative oral biofilms.
- P7. Willem Zoutman (*LUMC*) Diagnosing early cases of Sézary syndrome: Digital improvements in detection of DNA methylation biomarkers.
- P8. Rosanne Ottevanger *LUMC* Incidence of mycosis fungoides and Sézary syndrome in the Netherlands between 2000 and 2020.
- P9. Britt van der Leeden (*AmsterdamUMC*) METs and NETs are present in burn wound tissue and coincide with a procoagulant phenotype.
- P10. Clara Harrs (*UMCG*) Unravelling the aggressive behaviour of squamous cell carcinoma in epidermolysis bullosa: Analysis of clinical outcome and tumour characteristics in the Dutch EB Registry.
- P11. Jonas Jäger (*AmsterdamUMC*) Metabolically active, tri-layered reconstructed human skin.
- P12. Daphne van der Hout (*LUMC*) Epidemiology of Mycosis fungoides and Folliculotropic mycosis fungoides from 2000-2018.
- P13. Michelle Meertens (*UMCU*) First and second omalizumab treatment episode in chronic urticaria patients.
- P14. Reineke Soegiharto (*UMCU*) Clinical profile of adult patients with idiopathic angioedema.
- P16. Noline Post (*AmsterdamUMC*) Does autoimmune vitiligo protect against COVID-19 disease?
- P17. Lisa Pagan (*CHDR Leiden*) A systematic review of the vulvar microbiome in health and disease.
- P18. Jannik Rousel (*CHDR Leiden*) Results of a double-blind, randomized, placebo-controlled clinical trial with ketoconazole and placebo in seborrheic dermatitis.
- P19. Catharine Zhou (*ErasmusMC*) Primary melanoma characteristics of metastatic disease: a nationwide cancer registry study.
- P20. Celeste Eggermont (*ErasmusMC*) Nationwide data on patient profiles and patterns of care of patients with advanced cutaneous squamous cell carcinoma in The Netherlands.
- P21. Lieke van Delft (*MaastrichtUMC*) A patient decision aid for patients with a superficial basal cell carcinoma: hype or valuable?
- P22. Tamara van Hal (*Sint Maartenskliniek Nijmegen*) Discovery of arthritis in psoriasis for early rheumatologic referral (DAPPER): a cross-sectional study.
- P23. Elke ter Haar (*Radboudumc*) Drug survival and tolerability of biologics in older adult patients with psoriasis, a comparison with younger patients.
- P24. Yann Hoogland (*LUMC*) A nation-wide study to determine the tumour profile and risk in patients with the CDKN2A mutation.

- P25. Estella de Jong (*LUMC*) Cumulative incidence and risk factors for cutaneous squamous-cell carcinoma metastases in organ transplant recipients: the SCOPE-ITSCC metastases study.
- P26. Anna Zwanenburg (*AmsterdamUMC*) Predictors for recurrence, metastasis and mortality in primary cutaneous squamous cell carcinoma: a systematic review and meta-analysis.
- P27. Lara van der Schoot (*Radboudumc*) Implementation of a tightly controlled dose reduction strategy of adalimumab, etanercept and ustekinumab for psoriasis in daily clinical practice: a pilot study.
- P28. Celeste Boesjes (*UMCU*) Daily practice experience of baricitinib in patients with moderate to severe atopic dermatitis: a 16-week evaluation of clinical efficacy and safety.
- P29. Anouk Nouwen (*ErasmusMC*) Natural Moisturizing Factor as a clinical marker in atopic dermatitis.
- P30. Annelie Musters (*AmsterdamUMC*) COVID-19 outcomes in patients with atopic dermatitis: results from the global SECURE-AD physician registry.
- P31. Alet Leus (*UMCG*) The influence of frailty and life expectancy on treatment deviation and clinical outcome, including quality of life in patients with cutaneous squamous cell carcinoma of the head and neck – a prospective observational study.
- P32. Selinde Wind (*CHDR Leiden*) Topical bimiralisib, a dual pan-class PI3K/mTOR inhibitor, shows meaningful cutaneous drug levels in healthy volunteers and mycosis fungoides patients but no clinical activity.
- P33. Alet Leus (*UMCG*) Age-related differences in tumor characteristics and prognostic factors for disease progression in cutaneous squamous cell carcinoma of the head and neck.
- P34. Julia Clabbers (*MaastrichtUMC*) Alitretinoin as alternative treatment for inherited diseases of keratinization in childbearing age women – a case series and literature review.

16.45 - 17.30: **Guest Lecture by dr. Frank de Gruijl, LUMC**

17.30 - 20.00 **Drinks and Dinner**

20.00 - 20.45 **22th general assembly of the NVED**

20.45 - 01.00 **Party ? Having fun together ?**

Friday 24 June 2022

09.00 - 10.00 Session IV: Skin immunity and inflammation

Session chair: Ibrahim Korkmaz (*AmsterdamUMC*) + Jasper Koning (*AmsterdamUMC*)

13. Jasper Koning *AmsterdamUMC* A multi-organ-on-chip approach to investigate how oral exposure to metals can cause systemic toxicity leading to Langerhans Cell activation in skin.
14. Yixin Luo *LUMC* Assessment of Socs1 deletion in CD4+ T cells of chronically inflamed mouse skin to develop a pathogenic model of MF.
15. Luca Meesters *Radboudumc* Untangling the complex cytokine milieu in psoriasis and atopic dermatitis through in vitro epidermal models.
16. Jill Olydam *ErasmusMC* EASI p-EASI: predicting disease severity in atopic dermatitis patients treated with tralokinumab.

10.00 - 11.15 Poster walks (selected for poster prize) and networking session II (with coffee and tea)

11.15-12.30 Session V: Biologicals in dermatological practice

Session chair: Juul van den Reek (*Radboudumc*) + Louise Gerbens (*AmsterdamUMC*)

17. Marloes van Muijen *Radboudumc* Guselkumab drug survival is high in patients with psoriasis treated in real-world practice.
18. Roselie Achten *UMCU* Ocular surface disease is a common finding in moderate-to-severe atopic dermatitis patients.
19. Sarah Tomas *Radboudumc* 'Happy drug survival 2.0': drug survival combined with patient reported outcomes in psoriasis patients on biologics: results of the BioCAPTURE registry.
20. Lotte Spekhorst *UMCU* Successful tapering of dupilumab in patients with well-controlled AD.
21. Vanya Rossel *MaastrichtUMC* Expanding the spectrum of mutations for PNPLA1 and NIPAL4 in ichthyosis and evaluation of novel therapeutic interventions.

12.30 - 13.30 Lunch

13.30 - 14.15 Guest Lecture by dr. Henri Pas, *UMCG*

14.15 – 15.15 Session VI: Novel therapeutic strategies and treatment effects

Session chair: Abdoel El-Ghalbzouri (*LUMC*) + Antoni Gostynski (*MUMC*)

22. Shidi Wu *LUMC* Application of doxorubicin-loaded PLGA nanoparticles targeting both tumor cells and cancer-associated fibroblasts on human skin equivalents mimicking melanoma and cutaneous squamous cell carcinoma.
23. Babette Verkouteren *MaastrichtUMC* Eight years of experience with vismodegib for advanced and multiple basal cell carcinoma patients in the Netherlands.
24. Shima Ahmady *MaastrichtUMC* Risk of cutaneous squamous cell carcinoma after four different treatments for actinic keratosis: long-term results of a randomized controlled trial.
25. Nicoline Post *AmsterdamUMC* Meek micrografting: A novel surgical technique for the treatment of depigmentation.

15.15 - 15.25 Awards for best presentation and poster; selection breaking news

15.25 Closure

Meeting Location:

Congress hotel 'De Werelt'
Westhofflaan 2
6741 KH Lunteren
Tel: 0318-484641

Accreditation:

The NVDV has awarded 11 points for full participation in this scientific meeting last year; accreditation for 2022 is applied for

Program committee:

Michel van Geel (*MaastrichtUMC*), Ellen van den Bogaard (*Radboudumc*), Gilles Diercks (*UMCG*), Luba Pardo (*ErasmusMC*), Walbert Bakker (*AmsterdamUMC*), Judith Thijs (*UMCU*), Abdoel El-Ghalbzouri (*LUMC*)

Jury for presentation prize: Daphne Bakker (*UMCU*), Robert Rissmann (*CHDR*), Hanna Niehues (*Radboudumc*)

Jury for poster prize: Juul van den Reek (*Radboudumc*), Elsemieke Plasmeijer (*NKI*), Jeroen Bremer (*UMCG*)

NVED board:

Sue Gibbs (president, *AmsterdamUMC/ACTA*), Marcel Bekkenk (secretary, *AmsterdamUMC*), DirkJan Hijnen (representative in NVDV 'Commissie Nascholing', *ErasmusMC*), Antoni Gostynski (treasurer, *MUMC*), Patrick Zeeuwen (*Radboudumc*)